Low Glycemic Load Diet in Patients With Stage I-III Colon Cancer

NACompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

February 16, 2015

Primary Completion Date

June 14, 2018

Study Completion Date

July 10, 2018

Conditions
Stage I Colon CancerStage II Colon CancerStage III Colon CancerStage I Rectal CancerStage II Rectal CancerStage III Rectal Cancer
Interventions
OTHER

questionnaire administration

Ancillary studies including three day food record, twenty-four hour dietary recall, and a food acceptability questionnaire.

OTHER

laboratory biomarker analysis

Correlative studies

BEHAVIORAL

Standard Dietary Intervention

Participants will be contacted by a nutritionist, in person every 2 weeks with phone contact on the alternating weeks. At the initial visit, each participant will be given verbal and written patient education materials, including low glycemic load diet recipes, meal plans, food preparation, and grocery shopping information. Individual instruction will be tailored to their baseline dietary preferences (e.g. vegan, allergies, etc).

BEHAVIORAL

Intensified Dietary Intervention

Patients will be contacted weekly, in person, by a nutritionist . Participants will take part in a cooking demonstration at the time of their initial visit. The demonstration will be hands-on and participants will be able to sample foods and recipes. In addition to grocery shopping information, participants will be accompanied by a nutritionist to their local grocery store to practice new shopping habits for their target dietary glycemic load. Each participant will also receive weekly random phone calls to assess his or her progress.

BEHAVIORAL

Low glycemic load

BEHAVIORAL

Medium Glycemic Load

Trial Locations (2)

44106

Metrohealth Medical Center, Cleveland

44106-5065

Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Case Comprehensive Cancer Center

OTHER

NCT02129218 - Low Glycemic Load Diet in Patients With Stage I-III Colon Cancer | Biotech Hunter | Biotech Hunter